NCI Aug 18, 2022 CHOP, NCI Launch Big Data Resource to Spur Precision Pediatric Cancer Drug Development Premium Aug 5, 2022 Baylor College of Medicine Receives $5.5M NCI Grant for Several Liver Cancer Prevention Projects Aug 2, 2022 Envisagenics Wins $2M SBIR Grant From NCI for Splicing-Based Immunotherapy Target Discovery Platform Jul 6, 2022 Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Jun 27, 2022 Alaunos, NCI Expand Partnership to Explore Personalized Autologous T-Cell Therapy May 25, 2022 California Bill to Improve Precision Cancer Care Access for Medi-Cal Patients Sails Through Senate Apr 29, 2022 California Bill Aims to Give Medi-Cal Patients With Complex Cancers Access to Cutting-Edge Care Premium Apr 26, 2022 International LAGENO-BC Consortium Spurring Breast Cancer Genetics Research Across Latin America Premium Apr 14, 2022 Preclinical Data In Hand, City of Hope to Study Anti-TAG72 CAR T-Cell Therapy for Ovarian Cancer Apr 12, 2022 New Epigenomic Biomarker Could Predict CAR T-Cell Therapy Resistance in Advanced Childhood Leukemia Premium Apr 11, 2022 As NCI-MATCH Winds Down, Cancer Research Community Takes Stock of Lessons Learned Premium Mar 25, 2022 Initial KidsCanSeq Findings Reveal Medical Recommendations Stemming From Germline Tests Mar 21, 2022 NIH Launches New Childhood Cancer Genomics Program Mar 17, 2022 NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers Feb 3, 2022 Castle Biosciences Working With NCI on SEER Registry Study of DecisionDx-Melanoma Feb 2, 2022 President Biden Jumpstarts Cancer Moonshot Initiative With Goal of Halving Death Rate Jan 11, 2022 Neogene Therapeutics Licenses TCR Portfolio From NCI Jan 5, 2022 DiaCarta to Explore XNA Clamp Tech for Low-Frequency Mutations Under NIH Collaboration Nov 17, 2021 WUSTL Program Aims to Improve Sequencing Rates, Clinical Trial Participation Among Black Cancer Patients Premium Nov 15, 2021 Phosplatin Therapeutics Partners With NCI to Study PT-112 for Thymic Tumors Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
